Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Accumulated Expenses (2016 - 2026)

Mimedx's Accumulated Expenses history spans 16 years, with the latest figure at $14.5 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 22.51% to $14.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.5 million, a 22.51% decrease, with the full-year FY2025 number at $31.1 million, up 244.71% from a year prior.
  • Accumulated Expenses hit $14.5 million in Q1 2026 for Mimedx, down from $31.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for MDXG hit a ceiling of $31.1 million in Q4 2025 and a floor of $8.4 million in Q3 2024.
  • Historically, Accumulated Expenses has averaged $17.3 million across 5 years, with a median of $17.9 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: crashed 68.01% in 2022 and later surged 244.71% in 2025.
  • Tracing MDXG's Accumulated Expenses over 5 years: stood at $20.9 million in 2022, then increased by 7.18% to $22.4 million in 2023, then tumbled by 59.68% to $9.0 million in 2024, then surged by 244.71% to $31.1 million in 2025, then plummeted by 53.25% to $14.5 million in 2026.
  • Business Quant data shows Accumulated Expenses for MDXG at $14.5 million in Q1 2026, $31.1 million in Q4 2025, and $27.6 million in Q3 2025.